Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
22 hedge funds and large institutions have $337K invested in Agile Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less capital invested
Capital invested by funds: $372K → $337K (-$34.4K)
15% less funds holding
Funds holding: 26 → 22 (-4)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$8.07K |
| 2 |
HF
HRT Financial
New York
|
+$3.19K |
| 3 |
CWS
Confluence Wealth Services
Mcmurray,
Pennsylvania
|
+$2.89K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$1.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$11.3K |
| 2 |
Jane Street
New York
|
-$10.1K |
| 3 |
VF
Virtu Financial
New York
|
-$6.11K |
| 4 |
Renaissance Technologies
New York
|
-$5K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$3.97K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| – | -$13 | -1 | Closed |
|
AGRX Hedge Fund Activity: Q1 2023 in Review
22 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2023, worth a combined $337K — down 9.3% from $372K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of AGRX and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 1 added.
The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $8.07K. The largest seller was Sabby Management, exiting entirely with an estimated $11.3K sold.
- 22 institutional investors held Agile Therapeutics (AGRX) as of Q1 2023, down from 26 in Q4 2022.
- Funds reported $337K of Agile Therapeutics stock for Q1 2023, down 9.3% quarter-over-quarter.
- 3 funds opened new Agile Therapeutics positions in Q1 2023 and 6 closed out, a net change of -3 holders.
- The largest Agile Therapeutics buyer in Q1 2023 was Baader Bank Aktiengesellschaft, an estimated $8.07K added.
- The largest Agile Therapeutics seller in Q1 2023 was Sabby Management, an estimated $11.3K sold.
Based on aggregated 13F filings for Q1 2023.